Tin tức & Cập nhật
Xem bài viết Dược
Xem
Vedolizumab appears safe, effective in first-line treatment of ulcerative colitis in children
Children with ulcerative colitis seem to respond well to vedolizumab in the first-line setting, inducing remission without increasing the risk of adverse events, according to a small study.
PARG inhibition slows HCC progression, boosts efficacy of immune checkpoint therapy
In hepatocellular carcinoma (HCC), poly(ADP-ribose) glycohydrolase (PARG) may serve as an oncogene by modulating PARG/DDB1/c-Myc signaling and be used as a biomarker to identify HCC patients who may derive benefit from anti-PD-1 treatment, suggests a study.
Concurrent DOAC, tamoxifen use poses no elevated bleeding risk
In breast cancer patients receiving direct oral anticoagulants (DOACs), tamoxifen is safe to use and does not increase the risk of haemorrhage as compared with concurrent use of an aromatase inhibitor (AI), a study has found.
TNFi use carries only modest increase in psoriasis risk
The use of tumour necrosis factor-α inhibitor (TNFi) for inflammatory bowel disease (IBD) or rheumatoid arthritis (RA) raises the risk of developing psoriasis by twofold as compared with conventional therapy, although the absolute risk remains modest, as reported in a study.